Fig. 5. meR342-EZH2 promotes breast cancer tumorigenesis in vivo.

A Western blot assays confirmed knockdown EZH2 and overexpression of EZH2 in MDA-MB-231 cells. B, C Here, 5 × 10⁶ MDA-MB-231-Vector/Flag-EZH2-WT/Flag-EZH2-R342K cells were subcutaneously injected into each mice. n = 5 for each group. Four weeks after injection, the mice were killed and the xenograft tumours were collected (B), and the weight of the xenograft tumours was analysed (C). D, E IHC staining assays were performed in obtained xenograft tumours to detect EZH2, meR342-EZH2, P16, P21 and Ki67. F, G Here, 5 × 10⁶ MDA-MB-231 cells were subcutaneously injected into each mice. n = 5 for each group. Three weeks after injection, the mice were treated with GSK715 (100 mg/kg, each day) or PBS. After 10 days treatment with GSK715 or PBS, the nude mice were killed and the xenograft tumours were collected (F), and the weight of the xenograft tumours was analysed (G). H IHC staining assays were performed in collected xenograft tumours treated with GSK715 or PBS, to detect meR342-EZH2 and Ki67 expression.